Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 6
Submit an article Journal homepage
488
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series

Alejandro Garcia-HortonDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, CanadaORCID Iconhttps://orcid.org/0000-0003-0579-6709
ORCID Icon,
Dawn MazeDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
,
Caroline J. McNamaraDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
,
Hassan SibaiDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
,
Vikas GuptaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
&
Tracy MurphyDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, CanadaCorrespondence[email protected]
Pages 1525-1527 | Received 01 Oct 2020, Accepted 19 Dec 2020, Published online: 15 Jan 2021
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgements

This study was performed with the assistance of the Princess Margaret Leukemia Tissue Bank and the Elizabeth and Tony Comper Foundation to the MPN Program at the Princess Margaret Cancer Centre (V.G.).

Author contributions

The study was conceived by AGH and TM. AGH abstracted, collected, and analyzed the data. DM, CJM, HS, VG, and TM provided study patients. AGH and TM drafted the manuscript. All authors reviewed and approved the final version of the manuscript.

Disclosure statement

VG has served on the advisory board of Novartis, Celgene, Pfizer, and Sierra Oncology; received research funding from Novartis and Incyte. TM has served on advisory boards for Trillium Therapeutics. All other authors do not have conflicts of interest to declare.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.